Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/36261
Title: Growth hormone for risk stratification and effects of therapy in acute myocardial infarction
Authors: Ng, Leong Loke
Bhandari, Sanjay S.
Sandhu, Jatinderpal K.
Quinn, Paulene A.
Squire, Iain B.
Davies, Joan E.
Struck, J.
Bergmann, A.
Jones, Donald J.
First Published: 2-Nov-2015
Publisher: Taylor & Francis : STM, Behavioural Science and Public Health Titles
Citation: Biomarkers, 2015, 20 (6-7), pp. 371-375
Abstract: CONTEXT: Excess growth hormone (GH) is associated with early mortality. OBJECTIVES: We assessed the association of GH with prognosis after acute myocardial infarction (AMI), and the effects of secondary prevention therapies. METHODS: GH was measured using a high-sensitivity assay in 953 AMI patients (687 males, mean age 66.1 ± 12.8 years). RESULTS: During 2 years follow-up, there were 281 major adverse cardiac events (MACE). Patients with MACE had higher GH levels (median [range], 0.91 [0.04-26.28] μg/L) compared to event-free survivors (0.59 [0.02-21.6], p < 0.0005). In multivariate Cox survival analysis, GH was a significant predictor of MACE (hazard ratios 1.43, p = 0.026 and 1.49, p = 0.01, respectively) with significant interactions with beta blocker therapy (p = 0.047) and angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE/ARB) therapy (p = 0.016). CONCLUSIONS: GH levels post-AMI are prognostic for MACE and may indicate those patients who benefit from beta blocker and ACE/ARB therapy.
DOI Link: 10.3109/1354750X.2015.1093031
ISSN: 1354-750X
eISSN: 1366-5804
Links: http://www.tandfonline.com/doi/full/10.3109/1354750X.2015.1093031
http://hdl.handle.net/2381/36261
Embargo on file until: 2-Nov-2016
Version: Post-print
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © 2015, Taylor & Francis. All rights reserved. This is an Accepted Manuscript of an article published by Taylor & Francis in Biomarkers on 2 Nov 2015, available online: http://www.tandfonline.com/doi/abs/10.3109/1354750X.2015.1093031
Description: The file associated with this record is under a 12-month embargo from publication in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
File Description SizeFormat 
GHinAMI2015_Biomarkers.docxPost-review (final submitted)206.5 kBUnknownView/Open
GHinAMI2015_Biomarkers.pdfPost-review (final submitted)415.42 kBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.